In American patients with RA and no previous history of CVD, the risk of CVD was not significantly different between tofacitinib and TNF inhibitor users although a decreased risk was reported (pooled weighted HR: 0.81, 95% CI: 0.61–1.07) (Khosrow-Khavar et al., 2022). Here, TNF is linked to rheumatoid arthritis.